Laparoscopic sleeve gastrectomy induced 35.0% total weight loss and 66.7% diabetes remission at 24 months in adults with BMI >50 kg/m².
Observational (n=33)
No
Does primary laparoscopic sleeve gastrectomy improve weight loss and metabolic comorbidities in patients with super obesity (BMI >50 kg/m²)?
Laparoscopic sleeve gastrectomy in super-obese patients (BMI >50 kg/m²) provides substantial weight loss and high remission rates of metabolic comorbidities like diabetes and hypertension at 2 years, with a favorable safety profile.
Effect estimate: 35.0% total weight loss; 59.6% excess weight loss; 66.7% diabetes remission; 57.9% hypertension remission; 44.4% dyslipidemia remission
p-value: p=<0.0001 for HbA1c and HOMA-IR changes
Background: Patients with a body mass index (BMI) >50 kg/m² represent a major clinical challenge because of their high burden of metabolic comorbidities and increased mortality. Laparoscopic sleeve gastrectomy (LSG) is widely used as a primary bariatric procedure; however, evidence regarding its effectiveness in individuals with super obesity remains limited. This study aimed to evaluate weight loss and metabolic outcomes in patients with BMI >50 kg/m² who underwent LSG. Methods: We conducted an observational, retrospective, longitudinal study at the Centro Médico Nacional 20 de Noviembre, a tertiary care university hospital. Patients with BMI between 50 and 60 kg/m² who underwent primary LSG between January 2020 and December 2024 were included. The maximum institutional follow-up was 24 months. Anthropometric and metabolic variables were analyzed using paired Student’s t test or Wilcoxon test, whereas categorical variables were compared with the chi-square or Fisher’s exact test. Simple linear regression was performed, and statistical significance was set at p 50 kg/m² achieved substantial and clinically meaningful weight reduction, with most individuals meeting established criteria for surgical success at two years. The procedure was associated with significant improvement and high remission rates of major metabolic comorbidities, while maintaining a favorable safety profile and very low rates of weight regain. These findings support LSG as an effective primary strategy for super-obese patients within a structured multidisciplinary follow-up program. Our results contribute regional evidence that may assist decision-making and counseling in similar high-risk populations.
Montoya et al. (Mon,) conducted a observational in Adults aged 18-65 with super obesity (BMI 50-60 kg/m²) undergoing primary laparoscopic sleeve gastrectomy (n=33). Laparoscopic sleeve gastrectomy was evaluated on Sustained weight loss and metabolic remission at 24 months (35.0% total weight loss; 59.6% excess weight loss; 66.7% diabetes remission; 57.9% hypertension remission; 44.4% dyslipidemia remission, p=<0.0001 for HbA1c and HOMA-IR changes). Laparoscopic sleeve gastrectomy induced 35.0% total weight loss and 66.7% diabetes remission at 24 months in adults with BMI >50 kg/m².